We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genome Sequencing Detects Defects in Human Oocytes

By LabMedica International staff writers
Posted on 30 Dec 2013
A safe, accurate, and low-cost method to select genetically normal embryos for the in vitro fertilization (IVF) procedure can increase a couple's chance of producing a healthy child.

Through whole-genome sequencing of individual oocytes, the new method detects chromosomal abnormalities and DNA sequence variations associated with genetic disorders.

Scientists at the Peking University (Beijing, China) collaborating with colleagues at Harvard University (Cambridge, MA, USA) demonstrated genome analyses of single human oocytes using multiple annealing and looping-based amplification cycle (MALBAC)-based sequencing technology. More...
Various procedures are currently available to detect genetic defects in embryos prior to implantation, but these approaches are often invasive, requiring the removal of cells from the growing embryo, and do not simultaneously detect both chromosomal abnormalities and DNA sequence variations associated with genetic disorders.

The scientists developed a method for sequencing the entire genomes of polar bodies, which are cells that arise as a byproduct of egg cell division and often die later on. Because polar bodies are dispensable for human embryonic development, they can be safely removed without harming the embryo. The whole-genome sequencing methods simultaneously detect both types of defects in single human sperm cells, but until now, an analogous approach had not been applied to oocytes, even though chromosomal abnormalities are much more common in egg cells than in sperm cells.

By sequencing the first and second polar bodies, the scientists have provided proof of principle for a low-cost preimplantation genetic screening procedure of selecting fertilized eggs for transfer that are free of maternal aneuploidy and alleles associated with Mendelian diseases. The MALBAC sequencing offers improved resolution and accuracy of simultaneous detection of chromosome abnormality and heterozygous single nucleotide variants associated with Mendelian diseases.

Jie Qiao, MD, a senior author of the study said, “The new method detects chromosomal abnormalities and DNA sequence variations associated with genetic disorders. In this way, we kill two birds with one stone: one set of deep sequencing analysis to avoid two types of genetic problems. Theoretically, if this works perfectly, we will be able to double the success rate of test tube baby technology from 30% to 60% or even more.” The study was published on December 19, 2013, in the journal Cell.

Related Links:

Peking University
Harvard University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.